Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population

Atherosclerosis

Volumn 150, Issue 1, 2000, Pages 209-216

  Yamada, Yoshiji ^a   Yoshida, Hidemi ^b   Ichihara, Sahoko ^c   Imaizumi, Tadaatsu ^b   Satoh, Kei ^b   Yokota, Mitsuhiro ^c  

^a NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acetylhydrolase; Ageing; Atherosclerosis; Cerebral infarction; Myocardial infarction; Oxidized phospholipids; Platelet activating factor

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; PHOSPHOLIPASE A; THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGED; AGING; ARTERIOSCLEROSIS; ARTICLE; BLOOD; ENZYMOLOGY; FEMALE; GENETICS; GENOTYPE; HUMAN; JAPAN; MALE; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; POLYMERASE CHAIN REACTION; RISK FACTOR;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; AGED, 80 AND OVER; AGING; ARTERIOSCLEROSIS; FEMALE; GENOTYPE; HUMANS; JAPAN; MALE; MIDDLE AGED; MUTATION, MISSENSE; PHOSPHOLIPASES A; PLATELET ACTIVATING FACTOR; POLYMERASE CHAIN REACTION; RISK FACTORS;

EID: 0034181353     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00385-8     Document Type: Article

References (43)

1. Sytkowski PA, Kannel WB, D'Agostino RB. Changes in risk factors and the decline in mortality from cardiovascular diseass: The Framingham Heart Study. New Engl J Med 1990;322:1635-41.
2. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. New Engl J Med 1994;330:1041-6.
3. Honda Z, Nakamura M, Miki I, Minami M, Watanabe T, Seyama Y, Okado H, Toh H, Ito K, Miyamoto T, Shimizu T. Cloning by functional expression of platelet-activating factor receptor from guinea-pig lung. Nature 1991;349:342-6.
4. Zimmerman GA, Prescott SM, McIntyre TM. Platelet-activating factor and cell-associated mediator of inflammation. In: Gallin JI, Goldstein IM, Snyderman R, editors. Inflammation: Basic Principles and Clinical Correlates, 2nd ed. New York: Raven Press, 1992:149-76.
5. Imaizumi T, Stafforini DM, Yamada Y, McIntyre TM, Prescott SM, Zimmerman GA. Platelet-activating factor: a mediator for clinicians. J Intern Med 1995;238:5-20.
6. Mueller HW, Haught CA, McNatt JM, Cui K, Gaskell SJ, Johnston DA, Willerson JT. Measurement of platelet-activating factor in a canine model of coronary thrombosis and in endarterectomy samples from patients with advanced coronary artery disease. Circ Res 1995;77:54-63.
7. Patel KD, Zimmerman GA, Prescott SM, McIntyre TM. Novel leukocyte agonists are released by endothelial cells exposed to peroxide. J Biol Chem 1992;267:15168-75.
8. Prescott SM, Patel KD, Smiley PL, Stafforini DM, Lorant DE, Zimmerman GA, McIntyre TM. Potential roles for oxidized phospholipids in inflammation and atherogenesis. In: Weber PC, Leaf A, editors. Atherosclerosis Review, vol. 25. New York: Raven Press, 1993:59-68.
9. Smiley PL, Stremler KE, Prescott SM, Zimmerman GA, McIntyre TM. Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J Biol Chem 1991;266:11104-10.
10. Hockenbery DM, Oltvai ZN, Yin X-M, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993;75:241-51.
11. Sandstrom PA, Pardi D, Tebbey PW, Dudek RW, Terrian DM, Folks TM, Buttke TM. Lipid hydroperoxide-induced apoptosis: Lack of inhibition by Bcl-2 over-expression. FEBS Lett 1995;365:66-70.
12. Matsuzawa A, Hattori K, Aoki J, Arai H, Inoue K. Protection against oxidative stress-induced cell death by intracellular platelet-activating factor acetylhydrolase II. J Biol Chem 1997;272:32315-20.
13. Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: purification and properties. J Biol Chem 1987;262:4223-30.
14. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. Human plasma platelet-activating factor acetylhydrolase: association with lipoprotein particles and role in the degradation of platelet-activating factor. J Biol Chem 1987;262:4215-22.
15. Stremler KE, Stafforini DM, Prescott SM, Zimmerman GA, McIntyre TM. An oxidized derivative of phosphatidylcholine is a substrate for the platelet-activating factor acetylhydrolase from human plasma. J Biol Chem 1989;264:5331-4.
16. Stremler KE, Stafforini DM, Prescott SM, McIntyre TM. Human plasma platelet-activating factor acetylhydrolase: oxidatively fragmented phospholipids as substrates. J Biol Chem 1991;266:11095-103.
17. Yamada Y, Stafforini DM, Imaizumi T, Zimmerman GA, McIntyre TM, Prescott SM. Characterization of the platelet-activating factor acetylhydrolase from human plasma by heterologous expression in Xenopus laevis oocytes. Proc Natl Acad Sci USA 1994;91:10320-4.
18. Tselepis AD, Dentan C, Karabina S-AP, Chapman MJ, Ninio E. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma: catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995;15:1764-73.
19. Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein(a) in comparison with low density lipoprotein. J Biol Chem 1995;270:31151-7.
20. Stafforini DM, Zimmerman GA, McIntyre TM, Prescott SM. The platelet-activating factor acetylhydrolase from human plasma prevents oxidative modification of low-density lipoprotein. Trans Assoc Am Physicians 1992;105:44-63.
21. Watson AD, Navab M, Hama SY, Sevanian A, Prescott SM, Stafforini DM, McIntyre TM, La Du BN, Fogelman AM, Berliner JA. Effect of platelet activating factor-acetylhydrolase on the formation and action of minimally oxidized low density lipoprotein. J Clin Invest 1995;95:774-82.
22. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. New Engl J Med 1989;320:915-24.
23. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest 1991;88:1785-92.
24. Stafforini DM, Satoh K, Atkinson DL, Tjoelker LW, Eberhardt C, Yoshida H, Imaizumi T, Takamatsu S, Zimmerman GA, McIntyre TM, Gray PW, Prescott SM. Platelet-activating factor acetylhydrolase deficiency: A missense mutation near the active site of an anti-inflammatory phospholipase. J Clin Invest 1996;97:2784-91.
25. 994→T missense mutation in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism 1998;47:177-81.
26. 279→Phe) is a genetic risk factor for stroke. Stroke 1997;28:2417-20.
27. 994→T mis-sense mutation in the plasma platelet-activating factor acetylhydrolase gene with genetic susceptibility to nonfamilial dilated cardiomyopathy in Japanese. Circulation 1998;98:1881-5.
28. Satoh K, Imaizumi T, Yoshida H, Kawamura Y, Takamatsu S, Takamatsu M, Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoproteins of healthy men and women. Clin Chim Acta 1991;202:95-103.
29. Miyaura S, Maki N, Byrd W, Johnston JM. The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids 1991;26:1015-20.
30. Whisnant JP, Basford JR, Bernstein EF, Cooper ES, Dyken ML, Easton JD, Little JR, Marler JR, Millikan CH, Petito CK, Price TR, Raichle ME, Robertson JT, Thiele B, Walker MD, Zimmerman RA. Classification of cerebrovascular diseases III. Stroke 1990;21:637-76.
31. Ostermann G, Lang A, Holtz H, Ruhling K, Winkler L, Till U. The degradation of platelet-activating factor in serum and its discriminative value in atherosclerotic patients. Thromb Res 1988;52:529-40.
32. Ostermann G, Ruhling K, Zabel-Langhennig R, Winkler L, Schlag B, Till U. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. Thromb Res 1987;47:279-385.
33. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Takamatsu S, Mizuno S, Shoji B, Takamatsu M. Activity of platelet-activating factor (PAF) acetylhydrolase in plasma from patients with ischemic cerebrovascular diseases. Prostaglandins 1988;35:685-98.
34. Satoh K, Yoshida H, Imaizumi T, Takamatsu S, Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoproteins from patients with ischemic stroke. Stroke 1992;23:1090-2.
35. Graham RM, Stephens CJ, Sturm MJ, Taylor RR. Plasma platelet-activating factor degradation in patients with severe coronary artery disease. Clin Sci 1992;82:535-41.
36. Stephens CJ, Graham RM, Sturm MJ, Richadson M, Taylor RR. Variation in plasma platelet-activating factor degradation and serum lipids after acute myocardial infarction. Coron Artery Dis 1993;4:187-93.
37. Ruiz-Torres P, Gonzalez-Rubio M, Lucio Cazana FJ, Ruiz-Villaespesa A, Rodriguez-Puyol M, Rodriguez-Puyol D. Reactive oxygen species and platelet-activating factor synthesis in age-related glomerulosclerosis. J Lab Clin Med 1994;124:489-95.
38. Siren AL, Lin Y, Freuerstein G, Hallenbeck JM. Increased release of tumor necrosis factor-alpha into the cerebrospinal fluid and peripheral circulation of aged rats. Stroke 1993;24:880-6.
39. Miquel J, Ramirez-Bosca A, Soler A, Diez A, Carrion-Gutierrez MA, Diaz-Alperi J, Quintanilla-Ripoll E, Bernd A, Quintanilla-Almagro E. Increase with age of serum lipid peroxides: implications for the prevention of atherosclerosis. Mech Ageing Dev 1998;100:17-24.
40. Ando K, Beppu M, Kikugawa K. Evidence for accumulation of lipid hydroperoxides during the aging of human red blood cells in the circulation. Biol Pharm Bull 1995;18:659-63.
41. Satoh K, Imaizumi T, Kawamura Y, Yoshida H, Hiramoto M, Takamatsu S, Takamatsu M. Platelet-activating factor (PAF) stimulates the production of PAF acetylhydrolase by the human hepatoma cell line, Hep G2. J Clin Invest 1991;87:476-81.
42. Howard KM, Miller JE, Miwa M, Olson MS. Cell-specific regulation of expression of plasma-type platelet-activating factor acetylhydrolase in the liver. J Biol Chem 1997;272:27543-8.
43. Tew DG, Southan C, Rice SQJ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH. Purification, properties, sequencing, and cloning of a lipoprotein-associated, serine-dependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 1996;16:591-9.